Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 37944541

Fixed-duration ibrutinib-venetoclax versus chlorambucil-obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet Oncol
Publication date
2023 Dec
First author
Niemann CU

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2023 Dec;24(12):1294-1295. doi: 10.1016/S1470-2045(23)00485-0.
    note
    Source null
    related pmid
    37944540
    relationship
    Comment in
  2. citation
    Lancet Oncol. 2024 Feb;25(2):e54. doi: 10.1016/S1470-2045(23)00620-4.
    note
    Source null
    related pmid
    38301696
    relationship
    Comment in
  3. citation
    Lancet Oncol. 2024 Feb;25(2):e55. doi: 10.1016/S1470-2045(23)00677-0.
    note
    Source null
    related pmid
    38301697
    relationship
    Comment in

Authors and identifiers

  1. name
    Niemann CU
    type
    Author
  2. name
    Munir T
    type
    Author
  3. name
    Moreno C
    type
    Author
  4. name
    Owen C
    type
    Author
  5. name
    Follows GA
    type
    Author
  6. name
    Benjamini O
    type
    Author
  7. name
    Janssens A
    type
    Author
  8. name
    Levin MD
    type
    Author
  9. name
    Robak T
    type
    Author
  10. name
    Simkovic M
    type
    Author
  11. name
    Voloshin S
    type
    Author
  12. name
    Vorobyev V
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Niemann CU
    type
    Author
  2. name
    Munir T
    type
    Author
  3. name
    Moreno C
    type
    Author
  4. name
    Owen C
    type
    Author
  5. name
    Follows GA
    type
    Author
  6. name
    Benjamini O
    type
    Author
  7. name
    Janssens A
    type
    Author
  8. name
    Levin MD
    type
    Author
  9. name
    Robak T
    type
    Author
  10. name
    Simkovic M
    type
    Author
  11. name
    Voloshin S
    type
    Author
  12. name
    Vorobyev V
    type
    Author
bibliography ids
  1. nci-bib-7676b5cdffbbdb558594d1b5
book metadata
content sha256
c2a44a5199baa04b4cf7292b76bcabfc604531a551a55baf3491bdf23e0a4982
document type
citation
dois
  1. 10.1016/S1470-2045(23)00452-7
electronic publication date
display
2023 Nov 6
precision
day
year
2023
evidence scope
bibliographic_metadata_only
id
pubmed:37944541
immutable id
pubmed:37944541@c2a44a5199baa04b4cf7292b76bcabfc604531a551a55baf3491bdf23e0a4982
journal
abbreviation
Lancet Oncol
issn electronic
1474-5488
issn print
1470-2045
issue
12
name
The Lancet. Oncology
nlm unique id
100957246
pages
1423-1433
volume
24
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2023 Dec;24(12):1294-1295. doi: 10.1016/S1470-2045(23)00485-0.
    note
    Source null
    related pmid
    37944540
    relationship
    Comment in
  2. citation
    Lancet Oncol. 2024 Feb;25(2):e54. doi: 10.1016/S1470-2045(23)00620-4.
    note
    Source null
    related pmid
    38301696
    relationship
    Comment in
  3. citation
    Lancet Oncol. 2024 Feb;25(2):e55. doi: 10.1016/S1470-2045(23)00677-0.
    note
    Source null
    related pmid
    38301697
    relationship
    Comment in
outcomes validated
false
pmid
37944541
provenance
batch id
6d213eecf21b6b7867cb
provider
NCBI PubMed ESummary
record sha256
1650e4bcc092b2803c1c868f424e579653c5b7b76758a7023333908131d70969
response sha256
684f894a21d8f5f78a3bd0acd8ee4215ff94144487c53dab1056650ee8d6751d
retrieved at
2026-09-09T23:48:19.049083+00:00
publication date
display
2023 Dec
precision
month
year
2023
publication types
  1. Randomized Controlled Trial
  2. Multicenter Study
  3. Clinical Trial, Phase III
  4. Journal Article
  5. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/37944541/
title
Fixed-duration ibrutinib-venetoclax versus chlorambucil-obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial.

Preserved source evidence · Not medical advice